Table 2.

Characteristics of studies included in the descriptive review (n = 6 studies)

Study name and year	CTD-ILD subtype	Type of study	N	RTX Dose	Duration	Concurrent immunotherapy	Outcomes	Clinical follow-up	Adverse events with RTX	Primary reason for qualitative review
Sem et al. 2009	ASS-ILD	Case series	11	One cycle: 2-IV, 375 mg/ m2, monthly; 8-IV, 1000 mg administered on day 0 and day 14; 1–IV, 700 mg administered on day 0 and day 14	1 cycle	None	FVC; DLCO	6 months	1 infusion reaction	Provided only percentage improvements
Marie et al. 2012	ASS-ILD	Case series	7	One cycle: IV, 1000 mg administered on day 0 and day 14	1 cycle and another IV 1 g after 6 months	None	FVC; DLCO	1 year	None	No standard deviation data before and after treatment
Allenbach et al. 2015	ASS-ILD	Case series	10	One cycle: IV, 1000 mg administered on day 0 and day 14	1 cycle and another IV 1 g after 6 months	IVIG	FVC; DLCO	1 year	6 infections (not hospitalized)	No specific data on PFT change
Andersson et al. 2015	ASS-ILD	Case series	24	2- IV, 375 mg/ m2, monthly; 21-IV, 1000 mg administered on day 0 and day 14; 1- reduced dose because of perceived infection risk	Median number of cycles was 2.7	AZA, CYC, MMF	FVC; DLCO	10–60 months	6 infections (not hospitalized) and 1 purpuric rash	No standard deviation data before and after treatment
Chartrand et al. 2016	CTD-ILD	Cohort (retrospective)	24	One cycle: 22-IV, 1,000 mg administered on day 0 and day 14; 2-IV, 375 mg/ m.2, once weekly*4 weeks	14 ≥ 1 cycles	MMF, CYC	FVC	≥ 2 years	1 infusion reaction	Provided FVC curves but no raw data values
Vadillo et al. 2020	RA-ILD	Cohort (prospective)	31	Not mentioned specifically	Median number of cycles was 3.4	None	FVC; DLCO	6 years	1 infection and 1 pancytopenia	Provided only mean difference values without calculatable SD